drugset / Trial / NCT00005596

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00005596

RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which regimen of chemotherapy is more effective for acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is comparing four regimens of combination chemotherapy to see how well they work in treating children with newly diagnosed acute lymphoblastic leukemia.

Timeline

Start
2000-04
Primary completion
2005-07
Completion
2007-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified Intravenous
Subject Cytarabine Small molecule Intravenous
Subject Daunorubicin Small molecule 30 mg/m2 Intravenous
Subject Methotrexate Small molecule 1000 mg/m2 Intravenous
Subject Methotrexate Small molecule 2000 mg/m2 Intravenous
Subject Pegaspargase Protein / enzyme biologic 2500 unknown Intramuscular
Subject Thioguanine Small molecule 60 mg/m2 Oral
Background Dexamethasone Small molecule 6 mg/m2 Oral
Background Leucovorin Small molecule 5 mg/m2 Oral
Background MERCAPTOPURINE ANHYDROUS Small molecule 50 mg/m2 Oral
Background Vincristine Small molecule 1.5 mg/m2 Intravenous

Indications